Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Concord Biotech's PEG Ratio or its related term are showing as below:
NSE:CONCORDBIO'
s PEG Ratio Range Over the Past 10 Years
Min: 2.49 Med: 3.94 Max: 5.79
Current: 5.71
During the past 7 years, Concord Biotech's highest PEG Ratio was 5.79. The lowest was 2.49. And the median was 3.94.
NSE:CONCORDBIO's PEG Ratio is ranked worse than 80.61% of 98
companies
in the Biotechnology industry
Industry Median: 1.91
vs NSE:CONCORDBIO: 5.71
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Concord Biotech (NSE:CONCORDBIO) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Concord Biotech PEG Ratio Related Terms
Concord Biotech PEG Ratio Historical Data
* Premium members only.
The historical data trend for Concord Biotech's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CONCORDBIO vs VRTX, REGN, RVMD: PEG Ratio Comparison
For the Biotechnology subindustry, Concord Biotech's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Biotech PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Concord Biotech's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Concord Biotech's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Concord Biotech (NSE:CONCORDBIO) has a PEG Ratio of 5.71 as of Aug. 23, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Concord Biotech and its competitors. This is 45% above median its historical median of 3.94. Over the past decade, Concord Biotech's PEG Ratio has ranged from 2.49 to 5.79. According to the industry distribution chart, Concord Biotech ranks #79 out of 98 companies in the Biotechnology industry, placing it in the top 80.6%.
Is Concord Biotech's PEG Ratio too high?
Concord Biotech's current PEG Ratio of 5.71 is 45% above median its 10-year median of 3.94. Over the past 10 years, this metric has ranged from a low of 2.49 to a high of 5.79. The Biotechnology industry median PEG Ratio is 1.91. Concord Biotech's value of 5.71 is 199% above this industry median. Based on the distribution chart, Concord Biotech ranks #79 out of 98 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Concord Biotech has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Concord Biotech's PEG Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Concord Biotech ranks #79 out of 98 companies for PEG Ratio. This places Concord Biotech in the lower half of its industry. The industry median PEG Ratio is 1.91. Concord Biotech's value of 5.71 is 199% above this benchmark. Historically, Concord Biotech's own PEG Ratio has ranged from 2.49 to 5.79 over the past decade. While the company's 10-year median is 3.94 vs. the industry median of 1.91, Concord Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.91, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Concord Biotech's current PEG Ratio of 5.71 is 199% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Concord Biotech and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Concord Biotech's current PEG Ratio is 5.71, which is 45% above median its own 10-year median of 3.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Biotech stock overvalued right now?
Based on GuruFocus' analysis, Concord Biotech (NSE:CONCORDBIO) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,682.46, compared to a current price of ₹1,571.30 — trading 6.6% below its estimated fair value. The current PEG Ratio is 5.71, which is 45% above median its 10-year median of 3.94 and 199% above the Biotechnology industry median of 1.91. Concord Biotech's overall GF Score™ is 89/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Concord Biotech (NSE:CONCORDBIO), the current PEG Ratio is 5.71 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Biotech (NSE:CONCORDBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued.
The current stock price of ₹1,571.30 is trading 6.6% below its estimated GF Value™ of ₹1,682.46.
GuruFocus considers Concord Biotech to be Fairly Valued.
Key valuation signals for NSE:CONCORDBIO:
PEG Ratio: 5.71 (45% above median its 10-year median of 3.94)
GF Value™: ₹1,682.46 vs. price of ₹1,571.30 (6.6% below fair value)
Industry Position: 199% above the Biotechnology median (#79 of 98)
No single metric tells the full story. See the NSE:CONCORDBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
89GF Score
Get the complete analysis for NSE:CONCORDBIO
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CONCORDBIO has been successfully added to your 
